|
AU2007317242B2
(en)
|
2006-11-08 |
2013-08-01 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
|
|
EP3345905B1
(en)
|
2008-09-18 |
2021-09-01 |
Auspex Pharmaceuticals, Inc. |
Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
|
|
WO2011153157A2
(en)
*
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
JP6362601B2
(ja)
|
2012-09-18 |
2018-07-25 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP2951178A4
(en)
*
|
2013-01-31 |
2016-07-06 |
Auspex Pharmaceuticals Inc |
VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
|
|
WO2015048370A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
CA2930744A1
(en)
*
|
2013-12-03 |
2015-06-11 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
MX2016009817A
(es)
*
|
2014-01-27 |
2017-02-28 |
Auspex Pharmaceuticals Inc |
Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
|
|
CN106061506A
(zh)
*
|
2014-02-07 |
2016-10-26 |
纽罗克里生物科学有限公司 |
包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
|
|
EA201691582A1
(ru)
|
2014-02-07 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Новые фармацевтические препараты
|
|
PT3105218T
(pt)
|
2014-02-13 |
2019-12-05 |
Incyte Corp |
Ciclopropilaminas como inibidores de lsd1
|
|
KR20220140647A
(ko)
*
|
2014-05-06 |
2022-10-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
과다운동성 운동 장애의 치료를 위한 vmat2 억제제
|
|
MX375718B
(es)
|
2015-02-06 |
2025-03-06 |
Neurocrine Biosciences Inc |
[9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
|
|
IL288712B2
(en)
|
2015-03-06 |
2024-01-01 |
Auspex Pharmaceuticals Inc |
Methods for the treatment of abnormal involuntary movement disorders
|
|
EP3626720A1
(en)
|
2015-04-03 |
2020-03-25 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
CN113713108A
(zh)
*
|
2015-06-23 |
2021-11-30 |
纽罗克里生物科学有限公司 |
用于治疗神经学疾病或病症的vmat2抑制剂
|
|
KR102710120B1
(ko)
|
2015-08-12 |
2024-09-27 |
인사이트 홀딩스 코포레이션 |
Lsd1 저해제의 염
|
|
MX383906B
(es)
|
2015-10-09 |
2025-03-14 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
|
|
LT3875459T
(lt)
*
|
2015-10-30 |
2024-02-26 |
Neurocrine Biosciences, Inc. |
Valbenazino dihidrochlorido druskos ir jų polimorfai
|
|
CA3009169A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Neurocrine Biosciences, Inc. |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
EP3473623B1
(en)
*
|
2016-06-29 |
2020-07-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of nbi-98854, preparation method therefor and use thereof
|
|
RU2019110048A
(ru)
|
2016-10-06 |
2020-11-06 |
Ассиа Кемикал Индастрис Лтд. |
Твердые формы валбеназина
|
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
|
US10703750B2
(en)
|
2017-01-10 |
2020-07-07 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
JP7090151B2
(ja)
|
2017-01-27 |
2022-06-23 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
US10954235B2
(en)
|
2017-02-27 |
2021-03-23 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
WO2018170214A1
(en)
|
2017-03-15 |
2018-09-20 |
Zhang Chengzi |
Analogs of deutetrabenazine, their preparation and use
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
CN110691596A
(zh)
*
|
2017-04-01 |
2020-01-14 |
阿德普蒂奥制药有限公司 |
药物组合物
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
MA50175B1
(fr)
|
2017-09-21 |
2025-05-30 |
Neurocrine Biosciences, Inc. |
Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
|
|
AU2017435893B2
(en)
|
2017-10-10 |
2023-06-29 |
Neurocrine Biosciences, Inc |
Methods for the administration of certain VMAT2 inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2019094491A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
KR102776189B1
(ko)
|
2017-11-22 |
2025-03-04 |
아시아 케미컬 인더스트리스 리미티드 |
발베나진의 고상 형태
|
|
CA3086611C
(en)
|
2017-12-26 |
2023-07-25 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
WO2019241555A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
WO2020070236A1
(en)
|
2018-10-04 |
2020-04-09 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
WO2021027792A1
(zh)
*
|
2019-08-12 |
2021-02-18 |
山东绿叶制药有限公司 |
Vmat2抑制剂及其制备方法和应用
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN114423755A
(zh)
|
2019-09-13 |
2022-04-29 |
纽罗克里生物科学有限公司 |
用于合成缬苯那嗪的方法
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
HRP20250868T1
(hr)
|
2021-03-22 |
2025-09-26 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitori i postupci za uporabu
|
|
IL307826A
(en)
|
2021-04-26 |
2023-12-01 |
Neurocrine Biosciences Inc |
Processes for the synthesis of valbanazine
|
|
JP2024524324A
(ja)
|
2021-06-30 |
2024-07-05 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
統合失調症のアドオン処置において使用するためのバルベナジン
|
|
EP4362942A1
(en)
|
2021-06-30 |
2024-05-08 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
AU2023232134A1
(en)
|
2022-03-07 |
2024-10-03 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
JP2025531352A
(ja)
|
2022-09-21 |
2025-09-19 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
ヘキサヒドロ－２ｈ－ピリド［２，１－ａ］イソキノリンｖｍａｔ２阻害剤および使用の方法
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|